These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29337837)

  • 1. Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
    Weirthein J; Scolnik D; Milshtein NY; Capua T; Glatstein M
    Pediatr Emerg Care; 2019 Mar; 35(3):e44-e46. PubMed ID: 29337837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Massive intoxication with rivaroxaban, phenprocoumon, and diclofenac: A case report.
    Pfeiffer H; Herbst L; Schwarze B; Eckstein R; Weisbach V
    Medicine (Baltimore); 2016 Nov; 95(44):e5343. PubMed ID: 27858919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban: practical considerations for ensuring safety and efficacy.
    Smythe MA; Fanikos J; Gulseth MP; Wittkowsky AK; Spinler SA; Dager WE; Nutescu EA
    Pharmacotherapy; 2013 Nov; 33(11):1223-45. PubMed ID: 23712587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
    Piccini JP; Garg J; Patel MR; Lokhnygina Y; Goodman SG; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Mahaffey KW; Singer DE; Califf RM; Fox KA;
    Eur Heart J; 2014 Jul; 35(28):1873-80. PubMed ID: 24658769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
    Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rivaroxaban in high-risk patients].
    Špinar J; Špinarová L
    Vnitr Lek; 2017; 63(6):424-430. PubMed ID: 28840739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations.
    Repplinger DJ; Hoffman RS; Nelson LS; Hines EQ; Howland M; Su MK
    Clin Toxicol (Phila); 2016 Sep; 54(8):647-9. PubMed ID: 27251583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral anticoagulants for atrial fibrillation: a review of clinical trials.
    O'Dell KM; Igawa D; Hsin J
    Clin Ther; 2012 Apr; 34(4):894-901. PubMed ID: 22417716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.